This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Fnct Biotech, Inc. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Innovations by Jae Kyung Myung in Pulmonary Fibrosis Treatment
Introduction
Jae Kyung Myung is an accomplished inventor based in Seoul, South Korea. He has made significant contributions to the field of medical research, particularly in the treatment of pulmonary fibrosis. His innovative approach has led to the development of a unique patent that addresses this serious health condition.
Latest Patents
Jae Kyung Myung holds a patent for the "Use of G-CSF antibody for treatment of pulmonary fibrosis." This patent discloses a new use of M-CSF or G-CSF as a useful marker for the diagnosis or treatment of pulmonary fibrosis. The invention includes a composition containing M-CSF inhibitor and/or G-CSF inhibitor as active ingredients, which are suitable for preventing or treating pulmonary fibrosis. Furthermore, the composition binds to M-CSF and G-CSF, significantly inhibiting myofibroblast hyperplasia or pulmonary fibrosis of the pulmonary cells. This innovative approach has the potential to improve treatment outcomes for patients suffering from this debilitating disease.
Career Highlights
Jae Kyung Myung is currently associated with Fnct Biotech, Inc., where he continues to advance his research and development efforts. His work is characterized by a commitment to finding effective solutions for complex medical challenges. With a focus on innovative therapies, he has positioned himself as a key figure in the biotechnology sector.
Collaborations
Jae Kyung Myung collaborates with talented professionals in his field, including Su Jae Lee and Hae June Lee. These collaborations enhance the research environment and contribute to the development of groundbreaking treatments.
Conclusion
Jae Kyung Myung's contributions to the treatment of pulmonary fibrosis through his innovative patent demonstrate his dedication to advancing medical science. His work at Fnct Biotech, Inc. and collaborations with esteemed colleagues further highlight his impact in the field. The potential of his research to improve patient care is significant and promising.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile